Introduction
Methods
Participants
DMTB diagnosis
TB score evaluation
Inclusion criteria
Exclusion criteria
Sample size
Patients grouping
Data collection
Statistical analysis
Results
Baseline characteristics
Parameters | Low-score group (n = 261) | Middle-score group (n = 396) | High-score group (n = 106) | P values |
---|---|---|---|---|
Age (years), median (95% CI of median) | 54.7 (52.4–56.0) | 53.6 (51.0–53.9) | 54.9 (51.0–58.0) | 0.228 |
Male/female | 226/45 | 343/53 | 89/17 | 0.485 |
Smoking, cases (100%) | 76 (29.12) | 118 (29.8) | 32 (30.19) | 0.973 |
Chronic renal failure, cases (100%) | 27 (10.34) | 42 (10.61) | 12 (11.32) | 0.963 |
Previous history of malignancy, cases (100%) | 16 (6.13) | 28 (7.07) | 9 (8.49) | 0.716 |
Connective tissue disease, cases (100%) | 12 (4.6) | 17 (4.29) | 8 (7.55) | 0.370 |
Previous history of organ transplantation, cases (100%) | 4 (1.53) | 7 (1.77) | 2 (1.89) | 0.963 |
Cholesterol (mg/dL), median (95% CI of median) | 193.7 (191.0–197.2) | 200.0 (197.4–202.2) | 216.3 (210.8–221.9) | <0.0001 |
TG (mg/dL), median (95% CI of median) | 209.6 (206.9–211.2) | 229.7 (225.1–231.7) | 237.1 (229.9–244.4) | <0.0001 |
HDL (mg/dL), median (95% CI of median) | 53.4 (52.5–54.8) | 53.5 (52.4–54.2) | 53.9 (52.5–56.4) | 0.736 |
LDL (mg/dL), median (95% CI of median) | 154.4 (151.5–156.6) | 165.1 (161.9–166.7) | 174.3 (168.9–181.6) | <0.0001 |
Duration of tuberculosis (years) | 1.88 (1.80–1.92) | 2.19 (2.13–2.24) | 2.97 (2.90–3.09) | <0.0001 |
Duration of type-II DM (years), median (95% CI of median) | 9.85 (9.38–10.30) | 10.27 (9.89–10.65) | 10.87 (10.21–11.54) | <0.0001 |
Uncontrolled/controlled type-II DM (ratio) | 65/196 (0.33) | 189/207 (0.91) | 69/37 (1.86) | <0.0001 |
Leukocytes (cells/mm3) | 10,202 ± 634 | 11,822 ± 1042 | 14,752 ± 1299 | <0.0001 |
Lymphocytes (cells/mm3) | 2118 ± 68 | 2297 ± 108 | 2495 ± 141 | <0.0001 |
(1) Typical CT findings | Low-score group (n = 261) | Middle-score group (n = 396) | High-score group (n = 106) | P values |
---|---|---|---|---|
Centrilobular micronodules (<3 mm), cases (%) | 20 (7.66) | 18 (4.55) | 4 (3.77) | 0.161 |
Nodules (3–10 mm), cases (100%) | 261 (100) | 396 (100) | 106 (100) | |
Nodules (>1 cm) | ||||
Tree-in-bud lesions, cases (%) | 59 (22.6) | 73 (18.4) | 26 (24.5) | 0.251 |
Cavities, number (%) | 133 (51) | 424 (107.1) | 159 (150) | <0.0001 |
Cavities, diameters (cm), median (95% CI of median) | 0.72 (0.66–0.77) | 1.20 (1.09–1.28) | 3.45 (2.92–3.94) | <0.0001 |
Endobronchial lesion | ||||
Small airway wall thickening (lumen <80% of total), cases (%) | 16 (6.1) | 29 (7.3) | 7 (6.6) | 0.241 |
Bronchiolectasis/Bronchiectasis, cases (%) | 11 (4.2) | 15 (3.8) | 25 (23.6) | <0.0001 |
(2) Atypical CT findings | ||||
Interlobular septal thickening | ||||
Ground glass opacities, cases (%) | 5 (1.9) | 10 (2.5) | 3 (2.8) | 0.830 |
Consolidation, cases (%) | 31 (11.9) | 49 (12.4) | 37 (34.9) | <0.0001 |
Pleural effusion, cases (%) | 13 (5) | 15 (3.8) | 6 (5.7) | 0.623 |
Random micronodules (<3 mm), cases (%) | 16 (6.1) | 19 (4.8) | 8 (7.5) | 0.504 |
Cluster micronodules, cases (%) | 28 (10.7) | 47 (11.9) | 29 (27.4) | <0.0001 |
Reversed halo sign |